Genomic signature of colon cancer may individualise treatment

Researchers in the Duke Institute for Genome Sciences and Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens...

Read the whole article on

More from